Dare Bioscience Inc (DARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dare Bioscience Inc (DARE) has a cash flow conversion efficiency ratio of 0.508x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.44 Million) by net assets ($2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DARE company net worth for the company's overall valuation and market capitalisation.
Dare Bioscience Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Dare Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dare Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dare Bioscience Inc ranked by their cash flow conversion efficiency. Explore DARE cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOLDSTORM METALS CORP.
F:B2U
|
-0.009x |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
N/A |
|
Avrasya Petrol ve Turistik Tesisler Yatirimlar AS
IS:AVTUR
|
0.010x |
|
Mustera Property Group Ltd
AU:MPX
|
0.201x |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
-0.061x |
|
Healthcare Triangle Inc
NASDAQ:HCTI
|
-0.017x |
|
ESV Inc
KQ:223310
|
-0.403x |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Dare Bioscience Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Dare Bioscience Inc from 2011 to 2025. View Dare Bioscience Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.84 Million | $-9.89 Billion | -3477.715x | -387504.24% |
| 2024-12-31 | $-6.01 Million | $5.39 Million | -0.897x | -111.66% |
| 2023-12-31 | $-5.05 Million | $-38.86 Million | 7.698x | +572.90% |
| 2022-12-31 | $11.11 Million | $-18.09 Million | -1.628x | -119.32% |
| 2021-12-31 | $38.75 Million | $-28.76 Million | -0.742x | -103.39% |
| 2020-12-31 | $-1.15 Million | $-25.23 Million | 21.910x | +172.54% |
| 2019-12-31 | $440.83K | $-13.32 Million | -30.206x | -1878.71% |
| 2018-12-31 | $6.73 Million | $-10.27 Million | -1.527x | -698.85% |
| 2017-12-31 | $13.29 Million | $-2.54 Million | -0.191x | +92.53% |
| 2016-12-31 | $13.11 Million | $-33.54 Million | -2.558x | -290.65% |
| 2015-12-31 | $48.74 Million | $-31.91 Million | -0.655x | -55.70% |
| 2014-12-31 | $45.33 Million | $-19.06 Million | -0.421x | -107.06% |
| 2013-12-31 | $-2.79 Million | $-16.61 Million | 5.959x | +2170.70% |
| 2012-12-31 | $-80.04 Million | $-21.00 Million | 0.262x | +119.21% |
| 2011-12-31 | $12.35 Million | $-16.88 Million | -1.366x | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more